PeptiDream Inc.

Tokyo Stock Exchange 4587.T

PeptiDream Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 138.30 M

PeptiDream Inc. Cash and Short-Term Investments is USD 138.30 M for the year ending December 31, 2023, a 245.26% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

PeptiDream Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 40.06 M, a -60.74% change year over year.
PeptiDream Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 102.03 M, a 47.48% change year over year.
PeptiDream Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 69.18 M, a 7.63% change year over year.
PeptiDream Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 64.28 M, a 1.22% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4587.T

PeptiDream Inc.

CEO	Dr. Patrick Crawford Reid Ph.D.
IPO Date	June 12, 2013
Location	Japan
Headquarters	3-25-23 Tonomachi
Employees	745
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.

Key trends

Past 5 years